Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma

Lung adenocarcinoma (LUAD) is associated with a low survival rate at advanced stages. Although the development of targeted therapies has improved outcomes in LUAD patients with identified and specific genetic alterations, such as activating mutations on the epidermal growth factor receptor gene (EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: L’Hostis, Adèle, Palgen, Jean-Louis, Perrillat-Mercerot, Angélique, Peyronnet, Emmanuel, Jacob, Evgueni, Bosley, James, Duruisseaux, Michaël, Toueg, Raphaël, Lefèvre, Lucile, Kahoul, Riad, Ceres, Nicoletta, Monteiro, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390488/
https://www.ncbi.nlm.nih.gov/pubmed/37524705
http://dx.doi.org/10.1038/s41540-023-00292-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390488/
https://www.ncbi.nlm.nih.gov/pubmed/37524705
http://dx.doi.org/10.1038/s41540-023-00292-7

Ejemplares similares